secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-09-16T21:08:11+00:00
Accession:  0001213900-26-100574
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial amends warrant deals to reclassify $22.7M liability to equity, regain Nasdaq compliance
--------------------------------------------------------------------------------

- On Sep 16, 2026, amended Purchase and Note Exchange Agreements to remove Penalty Provision, add lock-up on warrant shares.
- Milestone Warrant rights reclassified from liability to equity: $19.7M (PIPE) and $3.0M (noteholders) to additional paid-in capital.
- Pro forma equity improves from $(38.4M) deficit to $22.9M positive as of Jun 30, 2026.
- Series A Preferred (12,930.617 shares) converts to 12.93M common shares; total common shares pro forma 15.56M.
- Amendments intended to satisfy Nasdaq continued listing and initial listing standards for change of control at Sep 17 Annual Meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026100574/0001213900-26-100574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026100574/ea0305675-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-100574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer